NDAORALTABLET
Approved
Nov 2023
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOQUEZNA (vonoprazan fumarate) is an oral potassium-competitive acid blocker (PCAB) approved in November 2023 for acid-related gastrointestinal conditions. It represents a novel mechanism class distinct from proton pump inhibitors (PPIs), offering potentially faster onset and different pharmacokinetic properties. The drug is taken by patients requiring gastric acid suppression for conditions such as erosive esophagitis or GERD.
$0.046BPart D
Growth3.8 years to LOEEarly-stage product in growth phase with minimal current spend signals emerging opportunity for commercial team expansion as market adoption accelerates.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.
Started Oct 2023
30 enrolled
Gastric Ulcer
Why This Matters for Your Career
Worked on VOQUEZNA at Phathom Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.